Israel Englander A Tyr Pharma Inc Transaction History

Millennium Management LLC

  • $224 Billion
  • Q1 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in A Tyr Pharma Inc stock. As of the latest transaction made, Millennium Management LLC holds 62,481 shares of LIFE stock, worth $97,470. This represents 0.0% of its overall portfolio holdings.

Number of Shares
62,481
Previous 125,226 50.11%
Holding current value
$97,470
Previous $176,000 31.25%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024
SELL
$1.42 - $2.02 $89,097 - $126,744
-62,745 Reduced 50.11%
62,481 $121,000
Q4 2023

Feb 14, 2024
SELL
$1.11 - $1.51 $251,834 - $342,585
-226,878 Reduced 64.43%
125,226 $176,000
Q2 2023

Aug 14, 2023
BUY
$1.72 - $2.57 $605,618 - $904,907
352,104 New
352,104 $760,000
Q4 2022

Feb 14, 2023
BUY
$2.02 - $2.49 $137,574 - $169,583
68,106 New
68,106 $149,000
Q1 2022

May 16, 2022
SELL
$4.75 - $7.54 $93,366 - $148,206
-19,656 Closed
0 $0
Q4 2021

Feb 14, 2022
SELL
$7.29 - $9.5 $31,434 - $40,964
-4,312 Reduced 17.99%
19,656 $147,000
Q3 2021

Nov 15, 2021
SELL
$4.22 - $12.48 $27,083 - $80,096
-6,418 Reduced 21.12%
23,968 $218,000
Q2 2021

Aug 16, 2021
BUY
$3.62 - $4.88 $109,997 - $148,283
30,386 New
30,386 $148,000
Q4 2020

Feb 16, 2021
SELL
$3.07 - $4.66 $69,906 - $106,112
-22,771 Closed
0 $0
Q3 2020

Nov 16, 2020
BUY
$3.23 - $5.39 $73,550 - $122,735
22,771 New
22,771 $74,000
Q2 2020

Aug 14, 2020
SELL
$2.55 - $4.58 $56,824 - $102,060
-22,284 Closed
0 $0
Q1 2020

May 14, 2020
BUY
$2.17 - $7.06 $48,356 - $157,325
22,284 New
22,284 $62,000

Others Institutions Holding LIFE

# of Institutions
59
Shares Held
33.5M
Call Options Held
7.5K
Put Options Held
3.2K
View Full List

About aTYR PHARMA INC

LIFE Quotes by TradingView
  • Ticker LIFE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,625,000
  • Market Cap $44.7M
  • Description
  • aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for ...
More about LIFE
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email